摘要
目的观察应用左西孟旦治疗顽固性心力衰竭临床疗效及安全性。方法选取本院收治的68例顽固性心衰的患者作为研究对象,随机分为观察组(常规治疗加入左西孟旦治疗)和对照组(常规治疗),比较两组临床治疗效果。结果观察组临床治疗总有效率为91.2%,对照组为70.6%,两组比较差异有统计学意义(P <0.05);治疗后观察组患者氨基末端脑钠肽前体、左室射血分数、每搏心输出量明显优于对照组,差异有统计学意义(P <0.05)。观察组不良反应发生率为8.8%,对照组为5.9%,组间比较差异无统计学意义(P> 0.05)。结论对于顽固性心衰患者采取左西孟旦治疗可明显改善患者相关临床症状,疗效显著,且安全性高。
Objective To explore the clinical efficacy and safety of levosimendan in the treatment of refractory heart failure. Methods A total of 68 patients with intractable heart failure were randomly divided into the observation group(routine treatment)and the control group(conventional treatment). The clinical effect of the two groups were compared. Results The total effective rate was 91.2% in the observation group and 70.6% in the control group(P<0.05). There were significant differences in amino-terminal pro-brain natriuretic peptide,left ventricular ejection fraction and cardiac output between observation group and control group(P <0.05). The incidence of adverse reaction was 8.8% in observation group and 5.9% in control group. There was no significant difference between the two groups(P>0.05). Conclusion Levosimendan therapy for patients with intractable heart failure can obviously improve the clinical symptoms of the patients. The curative effect is significant and the safety factor is high.
出处
《大医生》
2018年第9期22-23,共2页
Doctor
关键词
左西孟旦治疗
顽固性心衰
临床疗效
氨基末端脑钠肽前体
levosimendan treatment
refractory heart failure
clinical efficacy
N-terminal pro-brain natriuretic peptide precursor
作者简介
肖峰,硕士,住院医师,研究方向:脓毒症、感染性疾病。
